Pre-Conference Seminar Day
Monday, 13th March, 2023
Intro to ADCs
Your 101 Session for Beginners in the ADC Field
10:00 am Intro to ADCs
Synopsis
- Gain an understanding of the biological aspects of ADCs
- Choose an optimum antibody format
- Select the most appropriate ADC target which is easily accessible
- Learn about in vitro assays
- Assess key factors in evaluation of efficacy information from in vivo preclinical models
- Understand the choices and trade-offs in utilising the Chemistry ADC toolbox
- Evaluate payload choices for ADCs –
- Review linker design chemistry and what it can bring (“not just the piece in the middle”)
- Understand the impact of conjugation site selection on ADCs
- Gain familiarity with the fundamental early learnings that inform ADC design
- Learn about the key insights that allowed early investigators to overcome the initial challenges that hindered early ADC programmes
- Gain an understanding of key considerations in toxicology assessment of ADCs
- Gain an overview of the development process for ADCs
- Learn about the challenges and opportunities for further improvement upon ADC design
4:00 pm End of Seminar Day
1st ADCs in Combinations Day
Your Must Attend Session for Insight Into Combination Rationale & Best Practices on When & How to Combine Your ADCs
10:00 am Case Study: Highlighting the Advantages of Combining ADCs With Checkpoint Inhibitors
Synopsis
- Analysing positive preclinical data suggesting that the combination of
- ADCs with checkpoint inhibitors lead to increased tumour destruction and immunologic memory retention
- Outlining positive clinical results of combining ADCs with checkpoint inhibitors
10:30 am Panel Discussion: Can ADCs with Checkpoint Inhibitors
Synopsis
- Outlining ADCs as key partners in combination across indications
- Informing ADC combination development: right dose and schedule
- Emerging strategies to guide ADC combination development
11:00 am AbbVie’s Leading ADC Combination Therapies Pipeline
Synopsis
- Outlining AbbVie’s promising clinical data with respect to their antibody-drug conjugate pipeline
- Analysing clinical data previously presented at ASCO
- Outlining the future of this exciting technology
11:30 am Morning Refreshment Break
12:30 pm Exploring Challenges & New Opportunities for Combining Antibody Drug Conjugates & Cancer Immunotherapies
Synopsis
- Learning from the success of the combination of chemotherapies and Immuno-oncology (IO) drugs
- Discussing the successful combination of ADC and IO drugs in Cancer Therapeutics
- Outlining mechanism-based combination of IO drugs and ADCs to treat immunologically cold cancers
- Reviewing the challenges and opportunities to improve the therapeutic value of ADC and IO combinations
1:00 pm Analysing Specific Immune Combinations Including Checkpoint Inhibitors
Synopsis
- Discussing the rationale behind targeting immunostimulants or immunoinhibitory molecules
- Analysing specific immune combinations including checkpoint inhibitors, STING agonists, and TLR agonists
- Enhancing the fundamental understanding of the mechanisms and how we can design co-therapies to enhance the immune response
1:30 pm Lunch Break & Networking
2:30 pm Future Perspectives on Antibody Drug Conjugate Combination Development
Synopsis
- Outlining ADCs as key partners in combination across indications
- Informing ADC combination development: right dose and schedule
- Emerging strategies to guide ADC combination development
3:00 pm Roundtable Think Tank: What Are the Challenges With Manufacturing Multi Domain Drugs?
Synopsis
- Outlining the key process development and manufacturing challenges with developing multi domain drugs, and how to prepare for these throughout preclinical and clinical development
3:30 pm Roundtable Think Tank: Outlining the Analytical Challenges When Developing ADCs in Combinations
Synopsis
- Analysing how the current analytical tools for single-agent ADCs need to be adapted for analytical analysis of combination ADCs
- Discussing the new technologies that are necessary to serve this new field
4:00 pm End of Seminar Day
1st Next Generation ADCs Day
With a Growing Number of Non-Traditional Payloads Being Used in Preclinical & Clinical Development, this Seminar Day is Your One-stop-shop to Exploring the Opportunities Assoc
10:00 am An Overview of the Novel Conjugates Field
Synopsis
- Outlining the current clinical progress of non-cytotoxic payloads
- Discussing novel updates to the field since the last World ADC conference
- Discussing the various advantages of different novel conjugates, and whether companies should be incorporating them into their pipeline
10:30 am Case Study: Radiotherapeutics for Hematologic Malignancies?
Synopsis
- Discussing radio-conjugation methods, clinical development strategies, and identifying indications
- Exploring Waldenstroms macroglobulinemia, multiple myeloma, and lymphomas
- Planning for the market and future directions
11:00 am Case Study: A First-In-Class Peptide Drug Conjugate (PDC) Platform Targeting Sortilin (SORT1) Receptor Positive Cancers
Synopsis
- Understanding why the normal function of a scavenger receptor, SORT1, can be exploited to rapidly transport novel peptide drug conjugates (PDCs) into cancer cells
- Discussing the over expression of SORT1 in many solid tumours
- Learn about Thera’s lead PDC candidate, TH1902, across multiple solid tumours
- Review the potential of this novel SORT1+ platform for future developments
11:30 am Morning Refreshment Break
12:30 pm Outlining FAP-Targeted Small Molecule Conjugates for the Delivery of Biocidal Radionuclides to the Tumour Microenvironment
Synopsis
- Learn how OncoFAP is a portable and clinically validated tumour-homing moiety with a small organic structure
- Explore how OncoFAP-radionuclide conjugates efficiently accumulate to tumours after systemic administration in mice and patients, with exquisite selectivity for the target lesions
- Discuss how OncoFAP-Lutetium-177 derivatives potently induce anti-cancer activity in tumour bearing mice both in monotherapy and in combination with immunotherapy
1:00 pm Novel Methods for the Modification of Cysteines & Disulfides for the Construction of Antibody Conjugates, Chemical Bispecifics & “Synthetic Antibodies”
Synopsis
- Overview of the use of pyridazinediones (PDs) for the site-selective modification of full antibodies and antibody fragments
- Outlining recent highlights on chemical bispecific construction
- Exploring plug-and-play chemical-based antibody construction from fragments
1:30 pm Lunch Break & Networking
2:30 pm C’Dot Drug Conjugates (CDCs)- A Novel and Versatile Platform for the Targeted Tumor Delivery of a Wide Range of Payloads
Synopsis
- Description of the C'Dot platform
- Overview of preclinical and clinical experience
- Discussion of potential advantages over ADCs
3:00 pm Highlighting the Potential of Bicycle Conjugates to Target Solid Tumours
Synopsis
- Exploring the advantages of using bicyclic peptides in targeted therapies
- Discovering the potential of bicycle toxin conjugates and discussing their clinical
3:30 pm Bispecific XDC – A Versatile Drug Delivery Platform
Synopsis
- Design and mechanism of Bi-XDC: Leveraging bi-ligand synergies on multiple dimensions to drug the undruggable targets and pipeline of Bi- XDC platform Clinical Progress of CBP- 1008 and CBP-1018
4:00 pm End of Seminar Day
4th CMC Day
Address the Unique Late-Phase & Commercial Manufacturing Challenges that ADC Developers are Facing
10:00 am Discussing the Process of Choosing the Right CMO/CDMO & Outlining Appropriate Selection Criteria
Synopsis
- Deliberating on the appropriate selection criteria to prioritise when choosing the correct CMO/CDMO, including discussing the cost, quality, and speed triangle
- Articulating the current vendor landscape for manufacturing ADCs
10:30 am Roundtable Think Tank: Working Effectively With Your CMO to Minimise Manufacturing Timelines & Maximise Product Quality in Late-Stage Products
Synopsis
- Outlining key considerations to minimise manufacturing timelines, including effective communication, efficient processes, and accurate forward planning
11:00 am Enhancing Communication & Teamwork in Late-Stage Manufacturing
Synopsis
- Outlining the key considerations for streamlined process and analytical activities
- Understanding how your CDMO should become an extension of your development team during late-stage manufacturing
11:30 am Morning Refreshment Break
12:30 pm Roundtable Discussion: Understanding When & How to Scale Up CMC Effectively
Synopsis
- Exploring the most effective timelines for an effective scale up
- Discussing the best ways to prepare for scale up through early-stage development
- Setting the precedent for an efficient and safe CMC scale up
1:00 pm Outlining the Current CMC Regulatory Landscape for Late-Stage Manufacturing
Synopsis
- Outlining improvements in process development to ready yourself for late phase and commercial supply
- Highlighting the current regulatory environment and key specifications for Phase II development and beyond
1:30 pm Lunch Break & Networking
2:30 pm Panel Discussion: Highlighting Common Late-Stage Manufacturing Challenges & How to Pre-Empt Them
Synopsis
- Learning from those in the field who have faced and overcame late-stage manufacturing challenges
- Highlighting process changes that can be implemented to prepare for future challenges
- Selecting appropriate materials for use in process validation
- Outline strategies for addressing accelerated development when faced with the complex supply chain
3:00 pm Outlining the Challenges in Maintaining Robust Analytical Tools in Late-Stage Process Development
Synopsis
- Discussing the development of analytical techniques from Phase I-IV
- Outlining the challenges in identifying robust analytical tools suitable for complex antibody-drug conjugates
- Exploring the possibility of using real-time analytics in late-stage manufacturing
3:30 pm Working with CMOs – The HPAPI Safety Relationship
Synopsis
- Discussing potent drug safety and the customer/CMO relationship
- Exploring toxicological hazards and exposure risk assessments
- Analysing methods of controls and containment
- Expanding on procedures, training and awareness
- Outlining commercial, business and due diligence – HPAPI matters